Aibotics to Acquire Empulser Enterprises for Up to $22M in Series C Preferred Stock
AIBT has more than doubled off its 52-week low of $0.
Summary
Aibotics agreed to acquire Empulser Enterprises LLC for up to $22M in Series C Preferred Stock, with 90% of consideration tied to 36-month earn-out milestones. The deal includes up to $2M in pre-closing loans and a planned CEO transition. Patrick Tsang is joining as Strategic Advisor and intended CEO upon closing.
Updated with a Wiseek News report · What changed
Updates
· Wiseek News — AIBotics agreed to acquire Empulser for up to 2.2M Series C Preferred shares ($22M stated value), with Patrick Tsang joining as Strategic Advisor and intended CEO upon closing.
Key Events · M&A and Partnerships · AIBT
-
Updated · · Wiseek News
CEO Transition and Strategic Advisor Role
Patrick Tsang is expected to be appointed CEO and director of Aibotics upon closing, subject to background review and board approval. He is joining as Strategic Advisor and intended CEO upon closing.
-
Acquisition of Empulser Enterprises
Aibotics will acquire 100% of Empulser Enterprises LLC for up to $22,000,000 in Series C Preferred Stock, with 2,200,000 shares designated at a $10.00 per share original issue price.
-
Earn-Out Structure
Only 220,000 shares (10%) are issued at closing; the remaining 1,980,000 shares are allocated across 10 milestones over 36 months, including patent filings, product demonstrations, flight testing, and $500,000 in cumulative revenue.
-
Conversion Terms
Series C Preferred converts at the closing price of Aibotics common stock on the day before closing — at today's $0.0022 price, full conversion of all 2.2M shares would represent extreme dilution to existing common shareholders.
Analysis · AIBT · Life Sciences
Aibotics, a micro-cap with a going-concern warning and a $4.9M working capital deficit, is acquiring Empulser Enterprises LLC for up to $22 million in newly designated Series C Preferred Stock. The deal is structured with a 36-month earn-out tied to ten milestones — only 10% of the consideration is issued at closing, with the remaining 90% contingent on patent filings, product demonstrations, flight testing, and $500,000 in cumulative revenue. The conversion price of the Series C Preferred is set at the closing price of Aibotics' common stock on the day before closing, which at today's $0.0022 price would imply massive potential dilution if all milestones are achieved and shares are converted. The acquisition also includes up to $2 million in pre-closing secured loans to Empulser and a planned CEO transition to Patrick Tsang, who is joining as Strategic Advisor and intended CEO upon closing. For a company with substantial doubt about its ability to continue as a going concern, this transaction represents a strategic pivot that could either provide a path forward or further strain already limited resources.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIBT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.00 to $0.01. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.